Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | COPS5 | Q92905 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10230274 | 0.85 | NR1H4 (0.46) | CA1CA2EPHX2NR1H4RAB9A | |
| SCHEMBL15033676 | 0.81 | ASPH (0.44) | EPHX2NR1H4COPS5ASPHKDM8 | |
| SCHEMBL15033763 | 0.81 | PDE10A (0.52) | CA1CA2EPHX2NR1H4MEN1 | |
| SCHEMBL10231976 | 0.78 | NR1H4 (0.46) | CA1CA2EPHX2NR1H4RAB9A | |
| SCHEMBL15119866 | 0.78 | RXRA (0.48) | RAB9AL3MBTL1COPS5 | |
| SCHEMBL14998844 | 0.75 | CA1 (0.46) | CA1CA2EPHX2NR1H4MEN1 | |
| SCHEMBL14325832 | 0.75 | CCR2 (0.39) | CA1CA2MEN1NPC1RAB9A | |
| SCHEMBL12066151 | 0.74 | CA1 (0.45) | CA1CA2EPHX2NR1H4MEN1 | |
| SCHEMBL10231970 | 0.74 | KMT2A (0.49) | CA1CA2EPHX2NR1H4MEN1 | |
| SCHEMBL12065727 | 0.71 | EPHX2 (0.46) | CA1CA2EPHX2NR1H4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721025-B1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | CCR2, CCRL2, CXCR2 | CA1 3975/4885CA2 823/4885EPHX2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.